Stock research log
$ABBV Insider Trading
AbbVie Inc.
13
Alerts Listed
0
Insider Buys 30d
0
Insider Sells 30d
This page is InsiderWatch’s research log for ABBV: the alerts we sent on this stock, timestamped, plus recent insider buying and selling reported to the SEC on Form 4.
Price and Our Alerts
$ABBV price
Daily closing prices
3M change
+18.4%
1Y high
$294.89
1Y low
$197.38
Our alerts
13
in this window
Prices from public market data and may be delayed. Markers show the days our alerts on this stock fired. Not investment advice.
Our Alerts on $ABBV
| Sent (ET) | Call | Alert |
|---|---|---|
| Oct 30, 12:19 PM | NEUTRAL | AbbVie raises 2026 outlook on immunology, neuroscience beat |
| Oct 22, 9:14 AM | BULLISH | AbbVie skin-disease drug succeeds in late-stage trial |
| Oct 6, 11:33 AM | NEUTRAL | AbbVie lymphoma drug combo wins Phase 3 frontline trial |
| Sep 30, 1:41 AM | NEUTRAL | AbbVie posts positive Phase 2 eczema drug data |
| Sep 28, 8:06 AM | BULLISH | FDA approves AbbVie's Parkinson's drug JUVMO |
| Sep 24, 7:16 AM | NEUTRAL | AbbVie's Epkinly wins Canada follicular lymphoma nod |
| Sep 23, 5:44 AM | NEUTRAL | AbbVie wins EU nod for RINVOQ in pediatric arthritis |
| Sep 22, 2:22 AM | NEUTRAL | AbbVie wins EU approval for RINVOQ in children |
| Sep 14, 11:16 AM | NEUTRAL | AbbVie's Qulipta hits goal in menstrual migraine study |
| Sep 11, 10:34 AM | BULLISH | AbbVie's atogepant wins late-stage menstrual migraine trial |
| Sep 10, 9:01 AM | BULLISH | AbbVie's atogepant hits in menstrual migraine trial |
| Sep 4, 11:06 AM | NEUTRAL | AbbVie's etentamig hits Phase III myeloma goals |
| Sep 3, 9:16 AM | BULLISH | AbbVie posts positive Phase 3 myeloma readout |
Every alert we sent on ABBV is listed after a short delay, in the order it went out. The call shown is the one in the alert as sent.
Recent Insider Activity
Open-market buys and sells in ABBV by the company’s own officers, directors, and large holders, as reported to the SEC on Form 4 in roughly the last 30 days. New to the filing? Read what a Form 4 is and what the transaction codes mean.
| Filed (ET) | Insider | Action | Value |
|---|---|---|---|
| Aug 18 | Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER | SELL | $8.2M |
Sourced from public SEC Form 4 filings. Buys shown are open-market purchases; routine grants and plan sales are filtered out before a trade reaches this log.
Congress Trading in $ABBV
Members of Congress who disclosed trades in ABBV under the STOCK Act since we began tracking. Each name links to that member’s full page. Amounts are the disclosed ranges (see how the ranges work) and filings can arrive up to 45 days after the trade.
| Member | Action | Amount |
|---|---|---|
| Pete SessionsHouse | SELL | $15,001 - $50,000 |
| Josh GottheimerHouse | SELL | $1,001 - $15,000 |
| Julie JohnsonHouse | SELL | $1,001 - $15,000 |
| Julia LetlowHouse | SELL | $1,001 - $15,000 |
| Julia LetlowHouse | BUY | $1,001 - $15,000 |
| Julia LetlowHouse | SELL | $1,001 - $15,000 |
| Julia LetlowHouse | BUY | $1,001 - $15,000 |
Disclosed amounts are ranges. Filing and trade dates, who in the household traded, and full histories are part of the subscriber dashboard.
See the research log across all stocks, this week’s insider buying, or the congress trading tracker.
Get the Next ABBV Alert When It Fires.
Everything here is already public. Subscribers usually got it within minutes. Pro members get every alert. Free for 7 days, cancel any time.
Try Free for 7 DaysInsiderWatch is an informational research service based on publicly available information only and is not financial, investment, legal, or tax advice. The call shown is a reading of the event, not a recommendation to trade.